Month: April 2023

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, April 17, 2023, at 7:30 a.m. Eastern Time to discuss results from the Phase 2 study of VAX-24, the Company’s lead, broad-spectrum 24-valent pneumococcal conjugate vaccine (PCV) candidate, in adults aged 65 and older and full six-month safety data from both adult Phase 2 studies. To participate in the conference call, please dial (800)-267-6316 (domestic) or (203)-518-9783 (international) and refer to conference ID PCVX0417. A live webcast of the conference call will also be available on the investor relations page of the Vaxcyte corporate...

Following the breach in mediation between The Confederation of Norwegian Enterprise (NHO), the Confederation of the Vocational Unions (YS) and the Norwegian Labor Union (LO), employees organized in Industri Energi and FLT at Hydro Karmøy and Hydro Årdal will go on strike from Monday, April 17. The strike will gradually affect the operations at Hydro Karmøy and Hydro Årdal. The impact on operations is regulated by a separate agreement, which states how operations are to be reduced in a responsible manner and how both parties shall contribute. The affected members will go on strike gradually, as ramping down production requires considerable work effort from the operators at the aluminium plants. This process will take several months. Shipping activities will be strictly limited for both Hydro Årdal and Hydro Karmøy for the duration of the...

AFM13 demonstrated robust activity on the primary end point with an objective response rate (ORR) of 32.4% and 10.2% complete response rate (CR) in Intent to Treat (ITT) population Patients with Angioimmunoblastic T cell lymphoma (AITL), one of the most frequent subtypes of peripheral T Cell Lymphoma (PTCL), exhibited the highest ORR (53.3%) and CR (26.7%) Other measures of efficacy included median duration of response (DoR) of 2.3 months, median progression free survival (PFS) of 3.5 months and median overall survival (OS) of 13.8 months in advanced stage relapsed / refractory (r/r) PTCL patients Comparable response rates observed in patients with high and low CD30 expression levels and regardless of prior brentuximab vedotin treatment AFM13 exhibited a tolerable safety profile; most common treatment-emergent adverse events (TEAEs) were...

Abstracts demonstrating XNA technology’s improvements to assay sensitivity across different technology platforms and support for use in companion diagnostics (CDx) assay development Additional abstracts to further support XNA technology’s potential for use in minimal residual disease (MRD) monitoring of residual cancer cellsPLEASANTON, Calif., April 16, 2023 (GLOBE NEWSWIRE) — DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced that it will present five data posters at the American Association of Cancer Research (AACR) Annual Meeting 2023, which convenes in Orlando, Florida from April 14-19, 2023. The presentations will focus on how XNA can be used to improve the assay sensitivity of different technology platforms such as Sanger sequencing, qPCR, and Next Generation Sequencing (NGS). DiaCarta’s...

In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma (HCC) setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28%1 Up to 80% of people with this type of HCC experience disease recurrence, at which point they are faced with poorer prognosis and shorter survival2 These data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 and included in the official press programmeBasel, 16 April 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new data from the Phase III IMbrave050 study that show Tecentriq® (atezolizumab) plus Avastin® (bevacizumab) demonstrated a statistically significant improvement in recurrence-free survival (RFS) in people with hepatocellular carcinoma (HCC) at high risk of disease recurrence following liver resection...

In a release issued under the same headline on April 7, 2023 by Innospec Inc. (NASDAQ: IOSP), please note that the Online Registration Link has been updated. The corrected release follows. ENGLEWOOD, Colo., April 15, 2023 (GLOBE NEWSWIRE) — Innospec Inc. (NASDAQ: IOSP) today announced that it will release first quarter 2023 earnings results on Wednesday, May 3, 2023 after market close. Following the release of its results, Patrick S. Williams, President and Chief Executive Officer, and Ian Cleminson, Executive Vice President and Chief Financial Officer, will host an interactive conference call on Thursday, May 4, 2023, at 9:00 a.m. ET. The public is invited to listen to the conference call by registering in advance using the below Online Registration Link. Upon registering, each participant will receive an email confirmation with...

Rovio Entertainment Corporation        Inside information         15 April 2023, at 4:00 p.m. EEST Inside information: As part of its strategic review, Rovio Entertainment Corporation confirms that it is in discussions with Sega Sammy Holdings Inc. On February 6, 2023, Rovio Entertainment Corporation (“Rovio”) announced the commencement of a strategic review and preliminary non-binding discussions with certain parties in relation to a potential tender offer for Rovio’s shares. With reference to recent information in the media, Rovio confirms that it is in discussions with Sega Sammy Holdings Inc. (“Sega”) regarding a possible tender offer for Rovio’s shares. Rovio and Sega will release further information at an appropriate time. There is no certainty as to when the possible tender offer would take place or whether it would...

Short-term contract extension for Abo FPSO BW Offshore has signed a short-term extension for Abo FPSO with Nigerian Agip Exploration Ltd, a subsidiary of ENI S.p.A., until 30 April 2023. For further information, please contact:Ståle Andreassen, CFO, +47 91 71 86 55Anders S. Platou, Head of Corporate Finance & Strategy, +47 99 50 47 40 IR@bwoffshore.com or www.bwoffshore.com About BW Offshore:BW Offshore engineers innovative floating production solutions. The Company has a fleet of 9 FPSOs with potential and ambition to grow. By leveraging four decades of offshore operations and project execution, the Company creates tailored offshore energy solutions for evolving markets world-wide. BW Offshore has around 2,000 employees and is publicly listed on the Oslo Stock Exchange. This information is subject to the disclosure requirements pursuant...